glutathione s transferase inhibitor Discovery of potent inhibitors targeting S-transferase of Wuchereria bancrofti: a step toward the development of effective anti-filariasis drugs | Molecular Diversity Reengineering the glutathione S-transferase scaffold:

2019;59(5):e584e596

That included 35 preclinical studies and only one clinical study on humans

Strains carrying an HA-tagged version of Adh2 were generated by similar approaches using pYM-N16 (EG103 pGPD-3HA-ADH2 and EG110 pGPD-3HA-ADH2 ) or pYM-N14 (EG103 ADH2-6HA and EG110 ADH2-6HA ) as templates and primers ADH2_S1 and ADH2_S4 or 5-GGCATACTTGATAATGAAAACTATAAATCGTAAAGACATAAGAGATCCGCTTAATCGATGAATTCGAGCTCG-3 (ADH2_S2) and 5-AGATGGAGAAGGGCCAAATTGCTGGTAGATACGTTGTTGACACTTCTAAACGTACGCTGCAGGTCGAC-3(ADH2_S3), respectively

Some theoretical concerns (BPC-157 angiogenesis potentially problematic with anti-VEGF though no evidence of issues, peptides affecting blood pressure combined with pressure medications)

Preclinical studies in the published literature have examined BPC-157 in the context of connective-tissue cell migration assays, gastrointestinal epithelial models, and angiogenic signalling pathways